logo
My Secret to Low-Effort Supple Skin Is This Luxe Shower Oil

My Secret to Low-Effort Supple Skin Is This Luxe Shower Oil

New York Times14-04-2025

They say it's always darkest before the dawn. That was exactly the case when I found myself (and my bathroom) covered in body oil, trapped in my own personal episode of Naked and Afraid.
What led me to end up in such a humbling position? Dry skin, of course.
I hit the genetic lottery of having both dry and sensitive skin, so for me, a skin-care routine has always been essential. But I had never paid much attention to the skin below my neck. Partially because I dreaded the trial-and-error phase of trying new products, and partially because I absolutely hated the way moisturizer felt as it sunk into my skin.
But eventually, after years of ignoring the flurry of dead skin cells that came flying off of me at the end of each winter day, the state of my skin—or, should I say, husk—became unavoidable.
And so I went on a quest in search of the perfect product that would moisturize my thirsty skin without leaving me feeling greasy. I came out the other side with what would become my skin's hydration hero—L'Occitane Almond Shower Oil.
L'Occitane's Almond Shower Oil was among the plethora of solutions that popped up in my original search. I was intrigued by the fact that for about $45, I could buy a 16.9-ounce 100% recycled plastic bottle for refills, which would help me cut back on plastic waste. That factor, along with the French having a reputation for seemingly effortless, radiant beauty, had me quite tempted. But L'Occitane's 8.4-ounce bottle was nearly triple the price and about a third the size of similar drugstore products, so I figured cheaper alternatives had to be at least similarly effective.
I figured wrong.
Beauty influencers and magazines lauded the efficacy of various moisturizing body washes and oils. Yet with each one I tried, the results were mixed at best and left my entire bathroom covered in sticky oil at worst.
That moment of skidding around my bathroom was the final straw. I concluded that moisturized skin was not worth a slip and fall, so I quit my months-long search, figuring I'd just stay ashy forever.
And, as everyone who's ever seen a rom-com knows, the moment you stop looking is usually when you find exactly what you're looking for.
Serendipitously, while I was stocking up on my beauty essentials during a Sephora sale, I stumbled across a discount on the L'Occitane Almond Shower Oil and figured it was worth a shot. Cut to a year later, and this bottle of literal liquid gold is now one of my must-haves year-round, but especially during brutal winter weather.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Marc Garneau died after 'short but very difficult battle' with cancer, former staffer says
Marc Garneau died after 'short but very difficult battle' with cancer, former staffer says

Yahoo

time21 minutes ago

  • Yahoo

Marc Garneau died after 'short but very difficult battle' with cancer, former staffer says

Marc Garneau died this week after being diagnosed with two types of cancer earlier this year, his former staffer says. The first Canadian to travel to space and former cabinet minister died on Wednesday. He was 76. Marc Roy, Garneau's former chief of staff, told CBC's Power & Politicsthat the former minister had been diagnosed with lymphoma and leukemia earlier this year. "He fought a short but very difficult battle with two very rare types of cancer," Roy told host David Cochrane. "Although his diagnosis was only a couple of months ago, he was well until four or five weeks ago. So it went very, very quickly … it's a very, very tough loss." Roy said Garneau only shared his diagnosis with a small circle that agreed to respect his wish for privacy. "[It was] something he wanted to keep with his family so he could concentrate on his time with his family and not distract his family by the attention it could have gotten," Roy said. WATCH | It's a tragic loss,' says former chief of staff: Beyond his legacy as an astronaut, Garneau held a number of federal cabinet positions since 2015, including in transport and foreign affairs. Roy said Garneau was "tremendous" to work for as he reflected on his time in politics. "It's a huge loss to government. I think that his years in Ottawa are filled with many contributions to improving safety and expanding policy. I think he will be remembered for that for decades to come," Roy said. The House of Commons held another moment of silence for Garneau on Thursday and MPs took time to pay tribute to their former colleague. "He reminded us that Canadians can dream big, that we could aim for the stars quite literally," Government House leader Steve MacKinnon said. "He became a powerful symbol of the achievement and the accomplishment of this great country of ours." Like MacKinnon, other MPs reflected on how Garneau inspired Canadians. "Mr. Garneau, the future will always be inspired by your life, which was so inspiring for all Canadians," Conservative MP Gérard Deltell said in French. WATCH | Garneau's 'extraordinary ride': Bloc Québécois MP Rhéal Fortin said Garneau paved the way for other Canadians to journey to space, including Chris Hadfield and Julie Payette. "He showed us the way to the stars," Fortin said in French. Fighting back tears, Green Party Leader Elizabeth May said it was hard to say goodbye to "someone who was unfailingly kind [and] unfailingly respectful." "We've lost a very great human being, and to his entire family: my deepest condolences and sympathy — and know that in that space where he looks down at planet Earth now, I think it's a place called heaven."

Avicenna.ai scoops CE marks for two AI fracture detection tools
Avicenna.ai scoops CE marks for two AI fracture detection tools

Yahoo

time43 minutes ago

  • Yahoo

Avicenna.ai scoops CE marks for two AI fracture detection tools

French artificial intelligence (AI)-based medical imaging company has secured CE marks for a pair of radiologic screening tools to detect fractures from CT scans. CINA-VCF Quantix is an AI algorithm is used to detect unsuspected vertebral compression fractures (VCFs) in patients undergoing CT scans for unrelated conditions, while CINA-CSpine is designed for the detection and triage of cervical spine fractures. Both tools gained 510(k) clearance from the US Food and Drug Administration (FDA) in 2024, while the tools' receipt of CE mark follows clearance on five other AI tools in 2024 under the EU's Medical Device Regulation (EU MDR). For use in patients aged 50 and above who are undergoing patients undergoing CT scans of the chest or abdomen for other conditions, CINA-VCF Quantix automatically labels vertebrae and calculates vertebral height loss ratios in the thoracic and lumbar spine. In cases where a vertebral height loss ratio exceeds 20%–25%, a figure indicative of a moderate- to severe VCF, the algorithm generates prompts notifying radiologists to report their early findings in support of proactive patient care, Avicenna stated. co-founder and CEO, Cyril Di Grandi commented: "Osteoporotic vertebral fractures can have a profound impact on patients' quality of life. "By encouraging the reporting of VCF presence and severity, CINA-VCF Quantix has the potential to make a real difference in long-term patient outcomes." CINA-CSpine is designed to automatically flag suspected acute cervical spine fractures through radiologists' existing systems. Di Grandi continued: "The launch of CINA-CSpine in the European market marks a significant step forward in trauma care. By reducing the time between scan and diagnosis, we're helping radiologists catch cervical spine fractures faster and more reliably.' A 2023 report on AI in healthcare by GlobalData forecasts that global revenue for AI platforms across the sector will reach a valuation of almost $19bn by 2027, with the radiology field seeing some of the highest implementation of AI technologies. Research indicates that thoracolumbar fusion procedures, one of the most common spine surgery types, are in growing demand, with thoracolumbar procedures such as anterior lumbar interbody fusion (ALIF) and posterior lumbar fusion (PLF) in the US projected to see respective rises from 46,903 to 55,528 and 248,416 to 297,994 between 2020 and 2040. According to GlobalData, the spinal fusion market segment, of which thoracolumbar fusion is a part, is growing at a CAGR of 2.3% and forecast to reach a valuation of around $11.23bn by 2033. " scoops CE marks for two AI fracture detection tools" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati

Sanofi (SNY) Takes Bold $9.5Bn Immunology Leap
Sanofi (SNY) Takes Bold $9.5Bn Immunology Leap

Business Insider

time8 hours ago

  • Business Insider

Sanofi (SNY) Takes Bold $9.5Bn Immunology Leap

Sanofi (SNY) has its hands full—in the best way possible—after announcing its $9.5 billion acquisition of Blueprint Medicines. This marks the French pharma giant's fourth major strategic acquisition this year, but this deal stands out. Sanofi isn't just picking up a drug or two; it's gaining access to a robust immunology pipeline of internally developed therapies. In addition to securing Ayvakit, a treatment for systemic mastocytosis, the acquisition reinforces Sanofi's shift toward high-value biopharma assets. Despite recent stock underperformance, this bold move strengthens my long-term bullish outlook on Sanofi. Confident Investing Starts Here: Sanofi's Strategic Pivot Towards High-Value Biopharma Sanofi's recent sale of Opella, its consumer healthcare division, highlights a broader strategic shift toward prioritizing high-margin biopharma operations. The company has seen major success with Dupixent—a blockbuster drug for inflammatory conditions like COPD and dermatitis, which generated over $13 billion in sales last year and now makes up nearly 30% of Sanofi's total revenue. This move underscores Sanofi's commitment to doubling down on its most profitable and innovative drug assets. Immediate Ayvakit Revenue Sanofi's acquisition of Blueprint, while a sizable investment, brings immediate benefits in both revenue diversification and pipeline strength. Ayvakit, approved for treating advanced systemic mastocytosis (AdvSM) in 2021 and indolent systemic mastocytosis (ISM) in 2023, addresses a rare disease with few treatment options. The drug generated $479 million in 2024, and Blueprint projected up to $720 million in revenue for 2025. With peak annual sales expected to reach around $2 billion before 2030, Ayvakit offers Sanofi a strong, near-term revenue driver, helping to de-risk the $9.1 billion upfront cost. Strategically, it's also a seamless addition to Sanofi's growing immunology portfolio. Boosting Sanofi's Immunology Future with Blueprint's Pipeline While Blueprint's pipeline includes several candidates, the spotlight is on two key assets: elenestinib and BLU-808. Elenestinib is a next-generation KIT D816V inhibitor currently in late-stage development for systemic mastocytosis (SM). It aims to improve upon the safety profile of Ayvakit, potentially appealing to patients who may avoid Ayvakit due to side effects such as fatigue and cognitive impairment, thereby expanding Sanofi's market share in SM. BLU-808, on the other hand, is an early-stage asset targeting a broader range of inflammatory conditions, including allergic asthma and allergic rhinoconjunctivitis. Unlike SM, these are far more prevalent diseases, offering significantly larger commercial opportunities. Importantly, BLU-808 is tied to two contingent value rights (CVRs), which are dependent on achieving specific development and regulatory milestones. These CVRs provide a layer of downside protection for Sanofi—if BLU-808 fails in clinical trials, the company's overall payout for the asset is reduced. Navigating Margin Pressures with Strategic Investment All of this comes against the backdrop of ongoing margin pressures for Sanofi. The company has already walked back its 2025 operating margin target of 32%, citing pricing pressures in its legacy general medicines segment and a ramp-up in R&D spending. While Sanofi remains active in diabetes with drugs like Lantus and Toujeo, these products now face significant pricing headwinds from generics, making them far less profitable than they once were. The Blueprint acquisition underscores Sanofi's renewed focus on innovation and high-margin biopharma assets. Though this pivot comes at the cost of near-term margin dilution, it reflects a longer-term strategy: investing in R&D today in hopes of developing the next wave of blockbuster therapies. In this context, Sanofi is clearly still in the midst of a strategic transformation—one currently anchored by the strong performance of Dupixent. Unlike previous 'bolt-on' deals that added just a drug or two, the Blueprint acquisition marks a more decisive step toward reshaping Sanofi's portfolio around premium, next-generation therapeutics. What is the Price Prediction for SNY Stock? On Wall Street, SNY sports a consensus Moderate Buy rating based on two Buy, three Hold, and zero Sell ratings in the past three months. Sanofi's average stock price target of $62.20 implies ~25% upside potential over the next 12 months. Last week, analyst Sachin Jain from Bank of America Securities maintained a Buy rating on SNY. The analyst was bullish on Sanofi's pipeline, particularly itepekimab, despite it failing in one of two Phase 3 trials for COPD. Moreover, he noted that 'Sanofi's low price-to-earnings ratio, reflecting limited pipeline upside, is seen as an opportunity given the promising data from these trials, indicating a potential R&D turnaround for the company.' Blueprint Deal Seals the Verdict on SNY In summary, Sanofi's acquisition of Blueprint offers both near-term revenue and long-term growth potential. Ayvakit serves as a valuable bolt-on asset, while pipeline candidates like elenestinib and BLU-808 significantly enhance Sanofi's immunology portfolio. More importantly, the deal reflects Sanofi's strategic pivot toward higher-margin biopharma assets at a time when older drugs like Lantus are facing profitability headwinds. Though the investment may pressure margins in the short run, it sets the stage for long-term growth in a high-value segment of the pharmaceutical market. Notably, the deal is expected to be EPS accretive by 2027, thanks to Ayvakit's revenue potential, which will help justify and offset a large portion of the upfront $9.5 billion cost. Overall, Sanofi has secured a promising set of assets at a reasonable valuation while extending its leadership in immunology beyond Dupixent. With a modest P/E ratio of 20.5 and a solid 3.27% dividend yield, SNY stands out as a compelling long-term investment opportunity for investors seeking to tap into the expanding biopharmaceutical space.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store